BRYANT DRONETTE: Open Payments
NPI 1780088526 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,765 in 256 payments from 24 companies in 2025. Trend: 2023 $3,513 · 2024 $3,672 · 2025 $4,765
Food & beverage: $4,686Education: $80
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 33 | $529 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $444 |
| Otsuka America Pharmaceutical, Inc. | 20 | $413 |
| Neurocrine BioSciences, Inc. | 21 | $393 |
| Teva Pharmaceuticals USA, Inc. | 19 | $384 |
| Vanda Pharmaceuticals Inc. | 12 | $299 |
| Axsome Therapeutics, Inc. | 12 | $255 |
| Braeburn Inc. | 12 | $247 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $244 |
| ABBVIE INC. | 18 | $241 |
Products named: CAPLYTA, INGREZZA, REXULTI, ARISTADA, FANAPT, Auvelity, BRIXADI, TRINTELLIX.
Industry payments across LA — which companies pay providers there.
